Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EBS
EBS logo

EBS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Emergent BioSolutions Inc (EBS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
8.500
1 Day change
1.43%
52 Week Range
14.060
Analysis Updated At
2026/06/26
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

EBS is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock is trending below key moving averages, momentum is weak, insider selling has accelerated, and there are no fresh news catalysts or strong proprietary buy signals. The options setup is bullish in put-call ratios, but that alone is not enough to override the current weak price trend and lack of positive fundamental momentum. Based on the current data, the better decision is to avoid buying now.

Technical Analysis

The technical picture is bearish. MACD histogram is slightly negative and expanding lower, showing weakening momentum. RSI_6 at 44.99 is neutral but below the midpoint, which does not support a strong entry. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the stock is in a downtrend. Price at 7.98 is below the pivot level of 8.079, with near-term support at 7.712 and resistance at 8.445. The stock trend model suggests limited downside over the next day and week, but only modest upside over the next month, which does not signal a strong long-term buy setup.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bullish by positioning, with a low put-call ratio for both open interest and volume, suggesting traders are leaning bullish. However, total option volume is modest at 131, and today's volume is below average versus recent activity, so conviction is limited. IV Rank at 9.55 and IV percentile at 26.98 indicate relatively low-to-moderate implied volatility, which makes options pricing less expensive, but the current options data is not strong enough to offset the weak technical trend.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
7

Positive Catalysts

  • ["Options positioning is bullish with low put-call ratios", "No major negative news was reported in the last week", "The stock is trading near support levels, which could attract short-term dip buyers"]

Neutral/Negative Catalysts

  • ["No news catalysts in the recent week", "Insiders are selling, and selling increased 140.86% over the last month", "Bearish moving average alignment indicates a downtrend", "MACD is negative and weakening", "No AI Stock Picker signal today", "No SwingMax signal recently", "Hedge funds are neutral with no significant accumulation trend", "No recent congress trading data", "No valuation or financial snapshot available to support a long-term fundamental buy case"]

Financial Performance

No usable latest-quarter financial snapshot was provided due to an error, so there is no reliable quarter-over-quarter growth assessment available. The latest quarter season cannot be confirmed from the dataset.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no evidence of improving Wall Street sentiment. Overall, the Wall Street view appears neutral to cautious based on the lack of positive updates and the weak trading tone.

Wall Street analysts forecast EBS stock price to rise
1 Analyst Rating
Wall Street analysts forecast EBS stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.380
sliders
Low
15
Averages
15
High
15
Current: 8.380
sliders
Low
15
Averages
15
High
15
H.C. Wainwright
Buy
downgrade
$15 -> $12
AI Analysis
2026-03-09
Reason
H.C. Wainwright
Price Target
$15 -> $12
AI Analysis
2026-03-09
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Emergent BioSolutions to $12 from $15 and keeps a Buy rating on the shares following the earnings miss. The firm cites lowered earnings expectations for the target cut.
JPMorgan
NULL -> Overweight
maintain
2025-12-02
Reason
JPMorgan
Price Target
2025-12-02
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Erste Group Bank to EUR 107 from EUR 102 and keeps an Overweight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EBS
Unlock Now

People Also Watch